Walleye Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Walleye Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,000	Closed	-$366K	–	5068
2025 Q4	$366K	Hold	3,000	–	–	﹤0.01%	3162
2025 Q3	$301K	Hold	3,000	–	–	﹤0.01%	3007
2025 Q2	$249K	Hold	3,000	–	–	﹤0.01%	3199
2025 Q1	$243K	Sell	3,000 -631,200	-100%	-$56.4M	﹤0.01%	3115
2024 Q4	$57.1M	Sell	634,200 -254,200	-29%	-$24.6M	0.14%	93
2024 Q3	$87.8M	Sell	888,400 -5,000	-0.6%	-$491K	0.18%	62
2024 Q2	$82.8M	Sell	893,400 -37,500	-4%	-$3.36M	0.15%	74
2024 Q1	$88.3M	Sell	930,900 -20,400	-2%	-$1.89M	0.16%	69
2023 Q4	$84.9M	Buy	951,300 +222,700	+31%	+$16.5M	0.18%	60
2023 Q3	$53.2M	Buy	728,600 +196,200	+37%	+$15.7M	0.14%	78
2023 Q2	$44.3M	Buy	+532,400	New	+$44.5M	0.16%	60

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Walleye Capital's XBI Position: Q1 2025 in Review

Walleye Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2025, closing a stake of 134,006 shares — an estimated $12M sold.

Walleye Capital first reported a position in XBI in Q4 2020 and held it in 5 quarters. The position peaked at $15.9M in Q3 2024. 682 funds tracked by Wall St. Rank hold XBI as of Q1 2025.

Walleye Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2025 after selling out during the quarter.
Walleye Capital sold 134,006 State Street SPDR S&P Biotech ETF shares in Q1 2025, an estimated $12M.
Walleye Capital first reported a position in State Street SPDR S&P Biotech ETF in Q4 2020 and held it in 5 quarters.
Walleye Capital's State Street SPDR S&P Biotech ETF position peaked at $15.9M in Q3 2024.
682 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.